A possible explanation for the larger effect size in patients with prevalent cases of SSc could be the difference in exposure to angiotensin-converting enzyme inhibitor (ACEi), which is the drug of choice for treating scleroderma renal crisis (SRC) (19, 20). The gene discussed is ACE; the disease is systemic sclerosis.